Holen Sie sich die Stockscreener-App
0.88
1.95%
-0.0175
Handel nachbörslich:
.90
0.02
+2.27%
Schlusskurs vom Vortag:
$0.8975
Offen:
$0.91
24-Stunden-Volumen:
113.72K
Relative Volume:
1.04
Marktkapitalisierung:
$4.45M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-736.70K
KGV:
-88.00
EPS:
-0.01
Netto-Cashflow:
$-4.14M
1W Leistung:
+19.70%
1M Leistung:
-8.09%
6M Leistung:
-8.33%
1J Leistung:
-38.47%
1-Tages-Spanne:
$0.86
$0.91
1-Wochen-Bereich:
$0.75
$0.9141
52-Wochen-Spanne:
$0.6608
$2.9799
Xortx Therapeutics Inc Stock (XRTX) Company Profile
Firmenname
Xortx Therapeutics Inc
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie XRTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XRTX
Xortx Therapeutics Inc
|
0.88 | 4.68M | 0 | -736.70K | -4.14M | -0.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Xortx Therapeutics Inc Aktie (XRTX) Neueste Nachrichten
Should you hold or exit XORTX Therapeutics Inc. nowJuly 2025 Trade Ideas & Verified Short-Term Trading Plans - Newser
XORTX Therapeutics Inc. stock daily chart insightsQuarterly Trade Review & Growth Focused Entry Reports - Newser
Sector ETF performance correlation with XORTX Therapeutics Inc.Volume Spike & Daily Market Momentum Tracking - Newser
Combining price and volume data for XORTX Therapeutics Inc.Weekly Trend Summary & Daily Growth Stock Tips - Newser
Using R and stats models for XORTX Therapeutics Inc. forecastingTrade Entry Summary & Breakout Confirmation Trade Signals - Newser
Published on: 2025-08-13 00:29:47 - Newser
Leading vs lagging indicators on XORTX Therapeutics Inc. performanceBuy/Sell Zone Confirmation Technical Analysis - Newser
Is XORTX Therapeutics Inc. stock overhyped or has real potentialFree Buy Signal Based on Chart Analysis - Newser
What Fibonacci levels say about XORTX Therapeutics Inc. rebound3-Year Equity Summary With Setup Insights - Newser
Why XORTX Therapeutics Inc. stock attracts strong analyst attentionDaily Stock Movement Forecast with Accuracy - Newser
How XORTX Therapeutics Inc. stock performs during market volatilityAlpha Generation Strategy with Low Volatility - Newser
Is XORTX Therapeutics Inc. stock poised for growthShort-Term AI-Based Stock Price Forecast - Newser
why xortx therapeutics inc. stock attracts strong analyst attentionFree Low Risk Equity Screener With Results - Newser
Has XORTX Therapeutics Inc. found a price floorPortfolio Safety Metrics and Return Analysis - Newser
Using fundamentals and technicals on XORTX Therapeutics Inc.Real Stock Picks With Setup Verification - Newser
Volume spikes in XORTX Therapeutics Inc. stock – what they meanSector-Wise Equity Performance Trend Forecast - Newser
XORTX Therapeutics XRTX 2025Q2 Earnings Preview Upside Potential on Strategic Partnerships - AInvest
Custom watchlist performance reports with XORTX Therapeutics Inc.Weekly Setup Summary for Risk Controlled Trades - Newser
Breakout Traders Target XORTX Therapeutics Inc. on Recovery SetupDaily Volume Spike Trading Signals Detected - metal.it
XORTX Therapeutics Completes $114,500 Private Placement to Fund Gout Programs - MSN
XORTX Completes USD $114,500 Private Placement - GlobeNewswire
XORTX Completes USD $114,500 Private Placement - GlobeNewswire Inc.
How sentiment analysis helps forecast XORTX Therapeutics Inc.Predictive Short-Term Market Reversal Alerts - Newser
Smart tools for monitoring XORTX Therapeutics Inc.’s price actionFast Return Equity Forecast With Logic - Newser
Xortx Therapeutics announces planned goals for 2026 - TipRanks
XORTX Therapeutics Advances Gout Program with Strategic 2025/2026 Goals - TipRanks
XORTX Provides Corporate Update and Planned Activities for 2025 / 2026 - GlobeNewswire
XORTX Reveals 12-Month FDA Filing Timeline for Revolutionary Gout Treatment: $700M Market Opportunity - Stock Titan
Chart overlay techniques for tracking XORTX Therapeutics Inc.Momentum Screener with Buy and Sell Areas - Newser
Is this a good reentry point in XORTX Therapeutics Inc.Momentum Stocks with Breakout Potential - Newser
Will XORTX Therapeutics Inc. continue its uptrendSmart Chart Forecasting with AI Algorithms - Newser
Can technical indicators confirm XORTX Therapeutics Inc.’s reversalConsistent Profit Signals with AI Models - Newser
Will earnings trigger a reversal in XORTX Therapeutics Inc.Low Risk High Confidence Watchlist Builder - Newser
Recovery Setup Building in XORTX Therapeutics Inc. Experts SayWeekly Watchlist of High Movers Released - beatles.ru
Finanzdaten der Xortx Therapeutics Inc-Aktie (XRTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):